IGF-1 is actually known to be related to poor survival and higher aggressiveness in RCC, and high IGF-1 level with established RCC may lead to impaired response to interleukin-2 (IL-2) therapy (33). The gene discussed is IGF1; the disease is renal cell carcinoma.